A Cerebrovascular Event After Single-Dose Administration of Recombinant Factor VIIa in a Patient with Esophageal Variceal Bleeding
Makaleler > Tam Makale · 2006
Yazarlar: Murat AKYILDIZ, İlker TURAN, Ahmet Ömer ÖZÜTEMİZ, Yucel BATUR, Tankut ILTER
Digestive Diseases and Sciences, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2006, cilt 51, ss 1647-1649
DOI: 10.1007/s10620-005-9023-y
Özet
Upper gastrointestinal bleeding (UGIB) is a life-threatening complication of cirrhosis that develops from esophageal varices in almost 70% of patients. The mortality rate from the bleeding episodes is reported to be 30% [1-4]. Standard management of UGIB of cirrhotic patients is vasoactive therapy combined with endoscopic procedures such as endoscopic sclerotherapy and band ligation [5]. Currently, it is reported that recombinant activated fVIIa (Novoseven, NovoNordisc) can correct the prothrombin time in decompensated cirrhotic patients and also can be used safely in Child's B and C cirrhotic patients with UGIB [6-8]. Herein, we describe the first case report in the literature of a cerebrovascular event after the administration of a single dose of fVIIa in a cirrhotic patient with esophageal variceal bleeding.